Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aggressive percutaneous transluminal coronary angioplasty (PTCA) as good as stenting:

This article was originally published in Clinica

Executive Summary

Conventional wisdom says stenting may reduce restenosis by scaffolding the coronary artery but new data from the Thoraxcenter in Rotterdam, Holland, suggest that it may simply be a function of larger initial dilation. Dr Patrick Serruys, professor of interventional cardiology and director of the cath lab at the Thoraxcenter, says patients given stent-like PTCA - dilation that reduces stenosis by at least 70% - had similar outcomes to stented patients. However a stent-like result is only achieved in about 35% of PTCA patients compared with 87% of those given stents in the Benestent-I trial (see Clinica No 669/70, p 24). Dr Serruys suggested that trials of provisional stenting should compare results to patients with stent-like PTCA results.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT087799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel